Chapter 118
Vascular Malformations
Laurence M. Boon,
Miikka Vikkula,
Laurence M. Boon
Centre for Vascular Anomalies, Division of Plastic Surgery, Cliniques Universitaires Saint Luc, University of Louvain, Brussels, Belgium
Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium
Search for more papers by this authorMiikka Vikkula
Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium
Search for more papers by this authorLaurence M. Boon,
Miikka Vikkula,
Laurence M. Boon
Centre for Vascular Anomalies, Division of Plastic Surgery, Cliniques Universitaires Saint Luc, University of Louvain, Brussels, Belgium
Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium
Search for more papers by this authorMiikka Vikkula
Human Molecular Genetics, de Duve Institute, University of Louvain, Brussels, Belgium
Search for more papers by this authorBook Editor(s):Peter Hoeger,
Veronica Kinsler,
Albert Yan,
John Harper,
Arnold Oranje,
Christine Bodemer,
Margarita Larralde,
David Luk, Vibhu Mendiratta,
Diana Purvis,
Peter Hoeger
Search for more papers by this authorVeronica Kinsler
Search for more papers by this authorAlbert Yan
Search for more papers by this authorJohn Harper
Search for more papers by this authorArnold Oranje
Search for more papers by this authorChristine Bodemer
Search for more papers by this authorMargarita Larralde
Search for more papers by this authorVibhu Mendiratta
Search for more papers by this authorDiana Purvis
Search for more papers by this authorSummary
Vascular malformations are caused by developmental errors that occur in utero. They can be localized or diffuse and occur in any body part, including the viscera. Some are inconsequential, whereas others cause cosmetic problems, functional disability or threaten life. Clinical features permit diagnosis in about 90% of superficial vascular malformations in paediatric patients. Radiological imaging is rarely necessary for diagnosis; it is needed to delineate the malformation, detect an associated anomaly and determine therapy. Interdisciplinary collaboration is necessary not only for diagnosis, but also for treatment. Mutations have been found in several familial and, more recently, in sporadic types of vascular malformations. This offers hope for new forms of treatment.
References
- Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982; 69: 412–22.
-
Boon LM, Vikkula M. Molecular genetics of vascular malformations. In: JB Mulliken (ed.) Vascular Anomalies: Hemangiomas and Malformations, 2nd edn. Oxford: Oxford University Press, 2013: 327–75.
10.1093/med/9780195145052.003.0009 Google Scholar
- Enjolras O, Riché MC, Mulliken JB, Merland J. Atlas des Hémangiomes et Malformations Vasculaires Superficielles. Paris: McGraw-Hill, 1990.
- Takahashi K, Mulliken JB, Kozakewich HP et al. Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest 1994; 93: 2357–64.
- Wassef M, Blei F, Adams D et al. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136: 203–14.
- Esterly NB. Cutaneous hemangiomas, vascular stains and malformations, and associated syndromes. Curr Probl Pediatr 1996; 26: 3–39.
- Enjolras O, Mulliken JB. The current management of vascular birthmarks. Pediatr Dermatol 1993; 10: 311–3.
- Enjolras O, Mulliken JB. Vascular tumors and vascular malformations (new issues). Adv Dermatol 1997; 13: 375–423.
- Enjolras O, Logeart I, Gelbert F et al. [Arteriovenous malformations: a study of 200 cases]. Ann Dermatol Venereol 2000; 127: 17–22.
- Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97–110.
- Shovlin CL, Sodhi V, McCarthy A et al. Estimates of maternal risks of pregnancy for women with hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): suggested approach for obstetric services. Br J Obstet Gynaecol 2008; 115: 1108–15.
- Hosman AE, Devlin HL, Silva BM, Shovlin CL. Specific cancer rates may differ in patients with hereditary haemorrhagic telangiectasia compared to controls. Orphanet J Rare Dis 2013; 8: 195.
- Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005; 15: 265–9.
- Revencu N, Boon LM, Mulliken JB et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast-flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008; 29: 959–65.
- Revencu N, Boon LM, Mendola A et al. RASA1 mutations and associated phenotypes in 68 families with capillary malformation-arteriovenous malformation. Hum Mutat 2013; 34: 1632–41.
-
Revencu N, Boon LM, Mulliken JB, Vikkula M.
RASA1 and capillary malformation-arteriovenous malformation. In: RP Erickson, A Wynshaw-Boris (eds) Inborn Errors of Development Molecular Basis of Clinical Disorders of Morphogenesis. New York: Oxford University Press, 2016: 1423–8.
10.1093/med/9780199934522.003.0084 Google Scholar
- Amyere M, Revencu N, Helaers R et al. Germline loss-of-function mutations in EPHB4 cause a second form of capillary malformation–arteriovenous malformation (CM-AVM2) deregulating RAS-MAPK signaling. Circulation 2017; 136: 1037–48.
- Couto JA, Huang AY, Konczyk DJ et al. Somatic MAP2K1 mutations are associated with extracranial arteriovenous malformation. Am J Hum Genet 2017; 100: 546–54.
- Eerola I, Boon LM, Mulliken JB et al. Capillary malformation-arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003; 73: 1240–9.
- Johnson DW, Berg JN, Baldwin MA et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189–95.
- McAllister KA, Grogg KM, Johnson DW et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345–51.
- Gallione CJ, Repetto GM, Legius E et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363(9412): 852–9.
- Wooderchak-Donahue WL, McDonald J, O'Fallon B et al. BMP9 mutations cause a vascular-anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013; 93: 530–7.
- Ola R, Dubrac A, Han J et al. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun 2016; 7: 13650.
- Vikkula M, Boon LM, Carraway KL, 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996; 87: 1181–90.
- Macmurdo CF, Wooderchak-Donahue W, Bayrak-Toydemir P et al. RASA1 somatic mutation and variable expressivity in capillary malformation/arteriovenous malformation (CM/AVM) syndrome. Am J Med Genet A 2016; 170: 1450–4.
- van der Geer P, Henkemeyer M, Jacks T, Pawson T. Aberrant Ras regulation and reduced p190 tyrosine phosphorylation in cells lacking p120-Gap. Mol Cell Biol 1997; 17: 1840–7.
- Henkemeyer M, Rossi DJ, Holmyard DP et al. Vascular system defects and neuronal apoptosis in mice lacking ras GTPase-activating protein. Nature 1995; 377(6551): 695–701.
- Kawasaki J, Aegerter S, Fevurly RD et al. RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity. J Clin Invest 2014; 124: 2774–84.
- Xiao Z, Carrasco R, Kinneer K et al. EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: implications for EphB4 as a cancer target. Cancer Biol Ther 2012; 13: 630–7.
- Zhou XP, Marsh DJ, Hampel H et al. Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis. Hum Mol Genet 2000; 9: 765–8.
- Marsh DJ, Dahia PL, Zheng Z et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 1997; 16: 333–4.
- Marsh DJ, Kum JB, Lunetta KL et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8: 1461–72.
- Celebi JT, Wanner M, Ping XL et al. Association of splicing defects in PTEN leading to exon skipping or partial intron retention in Cowden syndrome. Hum Genet 2000; 107: 234–8.
- Liu AS, Mulliken JB, Zurakowski D et al. Extracranial arteriovenous malformations: natural progression and recurrence after treatment. Plast Reconstr Surg 2010; 125: 1185–94.
- Paltiel HJ, Burrows PE, Kozakewich HP et al. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology 2000; 214: 747–54.
- Kohout MP, Hansen M, Pribaz JJ, Mulliken JB. Arteriovenous malformations of the head and neck: natural history and management. Plast Reconstr Surg 1998; 102: 643–54.
- Larralde M, Gonzalez V, Marietti R et al. Pseudo-Kaposi sarcoma with arteriovenous malformation. Pediatr Dermatol 2001; 18: 325–7.
- Enjolras O, Chapot R, Merland JJ. Vascular anomalies and the growth of limbs: a review. J Pediatr Orthop B 2004; 13: 349–57.
- Brégeat P. Brégeat syndrome. In: PJ Vinken, GW Bruyn (eds) Handbook of Clinical Neurology: The Phakomatoses. Amsterdam: North Holland Publishers, 1975: 474–9.
- Bhattacharya JJ, Luo CB, Suh DC et al. Wyburn–Mason or Bonnet–Dechaume–Blanc as cerebrofacial arteriovenous metameric syndromes (CAMS). A new concept and a new classification. Intervent Neuroradiol 2001; 7: 5–17.
- Jiarakongmun P, Alvarez A, Rodesch G, Lasjaunias P. Clinical course and angioarchitecture of cerebrofacial arteriovenous metameric syndromes: three demonstrative cases and literature review. Intervent Neuroradiol 2002; 8: 251–64.
- Hodes JE, Merland JJ, Casasco A et al. Spinal vascular malformations: endovascular therapy. Neurosurg Clin N Am 1994; 5: 497–509.
- Thiex R, Mulliken JB, Revencu N et al. A novel association between RASA1 mutations and spinal arteriovenous anomalies. Am J Neuroradiol 2010; 31: 775–9.
- Letteboer TG, Mager HJ, Snijder RJ et al. Genotype-phenotype relationship for localization and age distribution of telangiectases in hereditary hemorrhagic telangiectasia. Am J Med Genet A 2008; 146A: 2733–9.
- Bayrak-Toydemir P, McDonald J, Markewitz B et al. Genotype–phenotype correlation in hereditary haemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet Part A 2006; 140: 463.
- Shovlin, CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Review 2010; 24: 203–19. Bayrak-Toydemir P, McDonald J, Markewitz B et al. Genotype–phenotype correlation in hereditary haemorrhagic telangiectasia: mutations and manifestations. Am J Med Genet Part A 2006; 140: 463.
- Morgan T, McDonald J, Anderson C et al. Intracranial hemorrhage in infants and children with hereditary hemorrhagic telangiectasia (Osler–Weber–Rendu syndrome). Pediatrics 2002; 109:E12.
- Ference BA, Shannon TM, White RI, Jr et al. Life-threatening pulmonary hemorrhage with pulmonary arteriovenous malformations and hereditary hemorrhagic telangiectasia. Chest 1994; 106: 1387–90.
- Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17: 860–71.
- Sabba C, Pasculli G, Lenato GM et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007; 5: 1149–57.
- Eerola I, Boon LM, Watanabe S et al. Locus for susceptibility for familial capillary malformation ('port-wine stain') maps to 5q. Eur J Hum Genet 2002; 10: 375–80.
- Cohen MM, Jr. Vasculogenesis, angiogenesis, hemangiomas, and vascular malformations. Am J Med Genet 2002; 108: 265–74.
- Tan WH, Baris HN, Burrows PE et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007; 44: 594–602.
- Roudier-Pujol C, Enjolras O, Lacronique J et al. [Multifocal epithelioid hemangioendothelioma with partial remission after interferon alfa-2a treatment]. Ann Dermatol Venereol 1994; 121: 898–904.
- Burrows PE, Laor T, Paltiel H, Robertson RL. Diagnostic imaging in the evaluation of vascular birthmarks. Dermatol Clin 1998; 16: 455–88.
- Haneen S, Johanna H, Ulrich G et al. Mutation analysis of ‘Endoglin’ and ‘Activin receptor-like kinase’ genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique. BMC Medical Genetics 2009; 10: 53.
- ter Berg JW, Dippel DW, Habbema JD et al. Unruptured intracranial arteriovenous malformations with hereditary haemorrhagic telangiectasia. Neurosurgical treatment or not? Acta Neurochirurgica 1993; 121(1–2): 34–42.
- Kadoya C, Momota Y, Ikegami Y et al. Central nervous system arteriovenous malformations with hereditary hemorrhagic telangiectasia: report of a family with three cases. Surg Neurol 1994; 42: 234–9.
- Matsubara S, Mandzia JL, ter Brugge K et al. Angiographic and clinical characteristics of patients with cerebral arteriovenous malformations associated with hereditary hemorrhagic telangiectasia. Am J Neuroradiol 2000; 21: 1016–20.
- Maher CO, Piepgras DG, Brown RD, Jr et al. Cerebrovascular manifestations in 321 cases of hereditary hemorrhagic telangiectasia. Stroke 2001; 32: 877–82.
- McClinton MA. Tumors and aneurysms of the upper extremity. Hand Clinics 1993; 9: 151–69.
- Enjolras O, Borsik M, Herbreteau D, Merland JJ. [Management of arteriovenous malformations]. Ann Dermatol Venereol 1994; 121: 59–64.
- Wu JK, Bisdorff A, Gelbert F et al. Auricular arteriovenous malformation: evaluation, management, and outcome. Plast Reconstr Surg 2005; 115: 985–95.
- Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiographics 1994; 14: 623–43; quiz 45–6.
- Yakes WF, Rossi P, Odink H. How I do it. Arteriovenous malformation management. Cardiovasc Intervent Radiol 1996; 19: 65–71.
- Burrows PE, Mulliken JB, Fishman SJ et al. Pharmacological treatment of a diffuse arteriovenous malformation of the upper extremity in a child. J Craniofac Surg 2009; 20 Suppl 1: 597–602.
- Dupuis-Girod S, Ginon I, Saurin JC et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012; 307: 948–55.
- Lebrin F, Srun S, Raymond K et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420–8.
- Burrows PE, Fellows KE. Techniques for management of pediatric vascular anomalies. In: C Cope (ed) Current Techniques in Interventional Radiology. 2. Philadelphia: Current Medicine, 1995: 12–27.
- Dompmartin A, Labbe D, Barrellier MT, Theron J. Use of a regulating flap in the treatment of a large arteriovenous malformation of the scalp. Br J Plast Surg 1998; 51: 561–3.
- Enjolras O, Deffrennes D, Borsik M et al. [Vascular ‘tumors’ and the rules of their surgical management]. Ann Chir Plast Esthet 1998; 43: 455–89.
- Benndorf G, Campi A, Hell B et al. Endovascular management of a bleeding mandibular arteriovenous malformation by transfemoral venous embolization with NBCA. Am J Neuroradiol 2001; 22: 359–62.
- Sofocleous CT, Rosen RJ, Raskin K et al. Congenital vascular malformations in the hand and forearm. J Endovasc Ther 2001; 8: 484–94.
- White RI, Jr., Pollak J, Persing J et al. Long-term outcome of embolotherapy and surgery for high-flow extremity arteriovenous malformations. J Vasc Interv Radiol 2000; 11: 1285–95.
- Eerola I, McIntyre B, Vikkula M. Identification of eight novel 5'-exons in cerebral capillary malformation gene-1 (CCM1) encoding KRIT1. Biochim Biophys Acta 2001; 1517: 464–7.
- Sirvente J, Enjolras O, Wassef M et al. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol 2009; 23: 1066–72.
- Toll A, Parera E, Gimenez-Arnau AM, Pou A et al. Cutaneous venous malformations in familial cerebral cavernomatosis caused by KRIT1 gene mutations. Dermatology 2009; 218: 307–13.
- Boon LM, Vanwijck R. [Medical and surgical treatment of venous malformations]. Ann Chir Plast Esthet 2006; 51(4–5): 403–11.
- Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 2010; 25: 224–35.
- Limaye N, Boon LM, Vikkula M. From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet 2009; 18(R1): R65–74.
- Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet 2007; 16 Spec No. 2: R140–9.
- Wouters V, Limaye N, Uebelhoer M et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects. Eur J Hum Genet 2010; 18: 414–20.
- Brouillard P, Boon LM, Mulliken JB et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations (‘glomangiomas’). Am J Hum Genet 2002; 70: 866–74.
- Boon LM, Mulliken JB, Enjolras O, Vikkula M. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol 2004; 140: 971–6.
- Eerola I, Plate KH, Spiegel R et al. KRIT1 is mutated in hyperkeratotic cutaneous capillary-venous malformation associated with cerebral capillary malformation. Hum Mol Genet 2000; 9: 1351–5.
- Labauge P, Enjolras O, Bonerandi JJ et al. An association between autosomal dominant cerebral cavernomas and a distinctive hyperkeratotic cutaneous vascular malformation in 4 families. Ann Neurol 1999; 45: 250–4.
- Boon LM, Mulliken JB, Vikkula M et al. Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. Human Mol Genet 1994; 3: 1583–7.
- Gallione CJ, Pasyk KA, Boon LM et al. A gene for familial venous malformations maps to chromosome 9p in a second large kindred. J Med Genet 1995; 32: 197–9.
- Korpelainen EI, Karkkainen M, Gunji Y et al. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Oncogene 1999; 18: 1–8.
- Limaye N, Wouters V, Uebelhoer M et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009; 41: 118–24.
- Soblet J, Kangas J, Natynki M et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol 2017; 137: 207–16.
- Uebelhoer M, Natynki M, Kangas J et al. Venous malformation-causative TIE2 mutations mediate an AKT-dependent decrease in PDGFB. Hum Mol Genet 2013; 22: 3438–48.
- Nätynki M, Kangas J, Miinalainen I et al. Common and specific effects of TIE2 mutations causing venous malformations. Hum Mol Genet 2015; 24: 6374–89.
- Boon LM, Brouillard P, Irrthum A et al. A gene for inherited cutaneous venous anomalies (‘glomangiomas’) localizes to chromosome 1p21-22. Am J Hum Genet 1999; 65: 125–33.
- Irrthum A, Brouillard P, Enjolras O et al. Linkage disequilibrium narrows locus for venous malformation with glomus cells (VMGLOM) to a single 1.48 Mbp YAC. Eur J Hum Genet 2001; 9: 34–8.
- Brouillard P, Ghassibe M, Penington A et al. Four common glomulin mutations cause two thirds of glomuvenous malformations (‘familial glomangiomas’): evidence for a founder effect. J Med Genet 2005; 42: e13.
- Brouillard P, Boon LM, Mulliken JB et al. Mutations in novel factor, glomulin, are responsible for glomuvenous malformations (‘glomangiomas’). Am J Hum Genet 2002; 70: 866–74.
- Amyere M, Aerts V, Brouillard P et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 2013; 92: 188–96.
- Mallory SB, Enjolras O, Boon LM et al. Congenital plaque-type glomuvenous malformations presenting in childhood. Arch Dermatol 2006; 142: 892–6.
- Brouillard P, Enjolras O, Boon LM, Vikkula M. Glomulin and glomuvenous malformation. In: CJ Epstein, RP Erickson, A Wynshaw-Boris (eds) Inborn Errors of Development, 2nd edn. New York: Oxford University Press, 2008: 1561–5.
- Brouillard P, Boon LM, Revencu N et al. Genotypes and phenotypes of 162 families with a glomulin mutation. Mol Syndromol 2013; 4: 157–64.
- Limaye N, Kangas J, Mendola A et al. Somatic activating PIK3CA mutations cause venous malformation. Am J Hum Genet 2015; 97: 914–21.
- Boscolo E, Kang K-T, Limaye N et al. Venous malformation: from causative mutations to murine model and targeted therapy. J Clin Invest 2015; 125: 3491–504.
- Couvineau A, Wouters V, Bertrand G et al. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet 2008; 17: 2766–75.
- Pansuriya TC, van Eijk R, d'Adamo P et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011; 43: 1256–61.
- Amyere M, Dompmartin A, Wouters V et al. Common somatic alterations identified in maffucci syndrome by molecular karyotyping. Mol Syndromol 2014; 5: 259–67.
- Akers A, Al-Shahi Salman R, Awad IA et al. Synopsis of Guidelines for the Clinical Management of Cerebral Cavernous Malformations: Consensus Recommendations based on systematic literature review by the Angioma Alliance Scientific Advisory Board Clinical Experts Panel. Neurosurgery 2017; 80: 665–80.
- Laberge-le Couteulx S, Jung HH, Labauge P et al. Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet 1999; 23: 189–93.
- Revencu N, Vikkula M. Cerebral cavernous malformation: new molecular and clinical insights. J Med Genet 2006; 43: 716–21.
- Liquori CL, Berg MJ, Squitieri F et al. Deletions in CCM2 are a common cause of cerebral cavernous malformations. Am J Hum Genet 2007; 80: 69–75.
- Bergametti F, Denier C, Labauge P et al. Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet 2005; 76: 42–51.
- Boon L, Mulliken J, Enjolras O, Vikkula M. Glomuvenous malformation (glomangioma): distinct clinicopathologic and genetic entity. Arch Dermatol 2004; 140: 971–6.
- Enjolras O, Ciabrini D, Mazoyer E et al. Extensive pure venous malformations in the upper or lower limb: a review of 27 cases. J Am Acad Dermatol 1997; 36(2 Pt 1): 219–25.
- Hein KD, Mulliken JB, Kozakewich HP et al. Venous malformations of skeletal muscle. Plast Reconstr Surg 2002; 110: 1625–35.
- Schajowicz F, Rebecchini AC, Bosch-Mayol G. Intracortical haemangioma simulating osteoid osteoma. J Bone Joint Surg Br 1979; 61: 94–5.
- Ballieux F, Boon LM, Vikkula M. Blue bleb rubber nevus syndrome. Handb Clin Neurol 2015; 132: 223–30.
- Weiss SW, Enzinger FM. Spindle cell hemangioendothelioma. A low-grade angiosarcoma resembling a cavernous hemangioma and Kaposi's sarcoma. Am J Surg Pathol 1986; 10: 521–30.
- Johnson TE, Nasr AM, Nalbandian RM, Cappelen-Smith J. Enchondromatosis and hemangioma (Maffucci's syndrome) with orbital involvement. Am J Ophthalmol 1990; 110: 153–9.
- Kaplan RP, Wang JT, Amron DM, Kaplan L. Maffucci's syndrome: two case reports with a literature review. J Am Acad Dermatol 1993; 29: 894–9.
- Enjolras O, Wassef M, Merland JJ. [Maffucci syndrome: a false venous malformation? A case with hemangioendothelioma with fusiform cells]. Ann Dermatol Venereol 1998; 125: 512–5.
- Boukobza M, Enjolras O, Guichard JP et al. Cerebral developmental venous anomalies associated with head and neck venous malformations. Am J Neuroradiol 1996; 17: 987–94.
- Dompmartin A, Acher A, Thibon P et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008; 144: 873–7.
- Dompmartin A, Thibon P, Vikkula M, Boon LM. Oral contraceptive and D-Dimer level‚ a reply. Arch Dermatol 2009; 145: 210–1.
- Mazoyer E, Enjolras O, Laurian C et al. Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol 2002; 24: 243–51.
- Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. J Am Acad Dermatol 2007; 56: 353–70; quiz 71–4.
- Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations. Part II: associated syndromes. J Am Acad Dermatol 2007; 56: 541–64.
- Enjolras O, Wassef M, Mazoyer E et al. Infants with Kasabach-Merritt syndrome do not have ‘true’ hemangiomas. J Pediatr 1997; 130: 631–40.
- Sarkar M, Mulliken JB, Kozakewich HP et al.Thrombocytopenic coagulopathy (Kasabach–Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100: 1377–86.
- Konez D, Burrows PE, Mulliken JB. Cervicofacial venous maformations. MRI features and interventional strategies. Intervent Neuroradiol 2002; 8: 227–34.
- Trop I, Dubois J, Guibaud L et al. Soft-tissue venous malformations in pediatric and young adult patients: diagnosis with Doppler US. Radiology 1999; 212: 841–5.
- Wassef M, Vanwijck R, Clapuyt P et al. [Vascular tumours and malformations, classification, pathology and imaging]. Ann Chir Plast Esthet 2006; 51: 263–81.
- Goraya JS, Marwaha RK, Vatve M, Trehan A. Blue rubber bleb nevus syndrome: a cause for recurrent episodic severe anemia. Pediatr Hematol Oncol 1998; 15: 261–4.
- Ertem D, Acar Y, Kotiloglu E et al. Blue rubber bleb nevus syndrome. Pediatrics 2001; 107: 418–20.
- Mazoyer E, Enjolras O, Bisdorff A et al. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 2008; 144: 861–7.
- Hermans C, Dessomme B, Lambert C, Deneys V. [Venous malformations and coagulopathy]. Ann Chir Plast Esthet 2006; 51: 388–93.
- Dompmartin A, Ballieux F, Thibon P et al. Elevated D-dimer level in the differential diagnosis of venous malformations. Arch Dermatol 2009; 145: 1239–44.
- Boscolo E, Limaye N, Huang L et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest 2015; 125: 3491–504.
- Hammer J, Seront E, Dupont S et al. Rapamycin as treatment for complex vascular anomalies. submitted.
- Yuksekkaya H, Ozbek O, Keser M, Toy H. Blue rubber bleb nevus syndrome: successful treatment with sirolimus. Pediatrics 2012; 129: e1080–4.
- Dubois JM, Sebag GH, De Prost Y et al. Soft-tissue venous malformations in children: percutaneous sclerotherapy with Ethibloc. Radiology 1991; 180: 195–8.
- Herbreteau D, Riche MC, Enjolras O et al. [Venous vascular malformations and their treatment with Ethibloc]. Journal des maladies vasculaires 1992; 17: 50–3.
- Suh JS, Shin KH, Na JB et al. Venous malformations: sclerotherapy with a mixture of ethanol and lipiodol. Cardiovasc Intervent Radiol 1997; 20: 268–73.
- Berenguer B, Burrows PE, Zurakowski D, Mulliken JB. Sclerotherapy of craniofacial venous malformations: complications and results. Plast Reconstr Surg 1999; 104: 1–11; discussion 2–5.
- Hammer FD, Boon LM, Mathurin P, Vanwijck RR. Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. J Vasc Interv Radiol 2001; 12: 595–600.
- Mason KP, Michna E, Zurakowski D et al. Serum ethanol levels in children and adults after ethanol embolization or sclerotherapy for vascular anomalies. Radiology 2000; 217: 127–32.
- Chapot R, Laurent A, Enjolras O et al. Fatal cardiovascular collapse during ethanol sclerotherapy of a venous malformation. Intervent Neuroradiol 2002; 8: 321–4.
- Cabrera J, Cabrera J, Jr., Garcia-Olmedo MA, Redondo P. Treatment of venous malformations with sclerosant in microfoam form. Arch Dermatol 2003; 139: 1409–16.
- Li L, Feng J, Zeng XQ, Li YH. Fluoroscopy-guided foam sclerotherapy with sodium morrhuate for peripheral venous malformations: Preliminary experience. J Vasc Surg 2009; 49: 961–7.
- Forlee MV, Grouden M, Moore DJ, Shanik G. Stroke after varicose vein foam injection sclerotherapy. J Vasc Surg 2006; 43: 162–4.
- Dompmartin A, Labbe D, Theron J et al. [The use of an alcohol gel of ethyl cellulose in the treatment of venous malformations]. Rev Stomatol Chir Maxillofac 2000; 101: 30–2.
- Dompmartin A, Blaizot X, Théron J et al. Radio-opaque ethylcellulose-ethanol is a safe and efficient sclerosing agent for venous malformations. Eur Radiol 2011; 21: 2647–56.
- Sannier K, Dompmartin A, Théron J et al. A new sclerosing agent in the treatment of venous malformations. Study on 23 cases. Interven Radiol 2004; 10: 113–27.
- Boon LM, Bataille AC, Bernier V et al. [Medical treatment of juvenile hemangiomas]. Ann Chir Plast Esthet 2006; 51: 310–20.
- Pireau N, Boon LM, Poilvache P, Docquier PL. Surgical treatment of intra-articular knee venous malformations: when and how? J Pediatr Orthop 2016; 36: 316–22.
- Fishman SJ, Smithers CJ, Folkman J et al. Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg 2005; 241: 523–8.
- Gallagher PG, Mahoney MJ, Gosche JR. Cystic hygroma in the fetus and newborn. Sem Perinatol 1999; 23: 341–56.
- Tanriverdi HA, Hendrik HJ, Ertan AK et al. Hygroma colli cysticum: prenatal diagnosis and prognosis. Am J Perinatol 2001; 18: 415–20.
- Sybert VP, McCauley E. Turner's syndrome. New Engl J Med 2004; 351: 1227–38.
- Osborn AJ, Dickie P, Neilson DE et al. Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations. Hum Mol Genet 2015; 24: 926–38.
- Boscolo E, Coma S, Luks VL et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis 2015; 18: 151–62.
- Luks VL, Kamitaki N, Vivero MP et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr 2015; 166: 1048–54 e1–5.
- Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest 2014; 124: 898–904.
- Irrthum A, Karkkainen MJ, Devriendt K et al. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000; 67: 295–301.
- Evans AL, Bell R, Brice G et al. Identification of eight novel VEGFR-3 mutations in families with primary congenital lymphoedema. J Med Genet 2003; 40: 697–703.
- Irrthum A, Devriendt K, Chitayat D et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis-lymphedema-telangiectasia. Am J Hum Genet 2003; 72: 1470–8.
- Ghalamkarpour A, Holnthoner W, Saharinen P et al. Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. J Med Genet 2009; 46: 399–404.
- Mansour S, Brice GW, Jeffery S, Mortimer P. Lymphedema-distichiasis syndrome. In: RA Pagon, MP Adam, HH Ardinger et al. (eds) GeneReviews(R). Seattle, WA, 1993.
- Ostergaard P, Simpson MA, Mendola A et al. Mutations in KIF11 cause autosomal-dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet 2012; 90: 356–62.
- Schlogel MJ, Mendola A, Fastre E et al. No evidence of locus heterogeneity in familial microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome. Orphanet J Rare Dis 2015; 10: 52.
- Hennekam RC, Geerdink RA, Hamel BC et al. Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation. Am J Med Genet 1989; 34: 593–600.
- Alders M, Hogan BM, Gjini E et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 2009; 41: 1272–4.
- Connell F, Kalidas K, Ostergaard P et al. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet 2010; 127: 231–41.
- Ostergaard P, Simpson MA, Connell FC et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43: 929–31.
- Mendola A, Schlogel MJ, Ghalamkarpour A et al. Mutations in the VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol 2013; 4: 257–66.
- Hirayama T, Sabokbar A, Itonaga I et al. Cellular and humoral mechanisms of osteoclast formation and bone resorption in Gorham-Stout disease. J Pathol 2001; 195: 624–30.
- Gomez CS, Calonje E, Ferrar DW et al. Lymphangiomatosis of the limbs. Clinicopathologic analysis of a series with a good prognosis. Am J Surg Pathol 1995; 19: 125–33.
- Boyd JB, Mulliken JB, Kaban LB et al. Skeletal changes associated with vascular malformations. Plast Reconstr Surg 1984; 74: 789–97.
- Harris GJ, Sakol PJ, Bonavolonta G, De Conciliis C. An analysis of thirty cases of orbital lymphangioma. Pathophysiologic considerations and management recommendations. Ophthalmology 1990; 97: 1583–92.
- Alqahtani A, Nguyen LT, Flageole H et al. 25 years' experience with lymphangiomas in children. J Pediatr Surg 1999; 34: 1164–8.
- Orvidas LJ, Kasperbauer JL. Pediatric lymphangiomas of the head and neck. Ann Otol Rhinol Laryngol 2000; 109: 411–21.
- Padwa BL, Hayward PG, Ferraro NF, Mulliken JB. Cervicofacial lymphatic malformation: clinical course, surgical intervention, and pathogenesis of skeletal hypertrophy. Plast Reconstr Surg 1995; 95: 951–60.
- Hartl DM, Roger G, Denoyelle F et al. Extensive lymphangioma presenting with upper airway obstruction. Arch Otolaryngol–Head & Neck Surg 2000; 126: 1378–82.
- Konez O, Vyas PK, Goyal M. Disseminated lymphangiomatosis presenting with massive chylothorax. Pediatr Radiol 2000; 30: 35–7.
- Brice G, Child AH, Evans A et al. Milroy disease and the VEGFR-3 mutation phenotype. J Med Genet 2005; 42: 98–102.
- Ghalamkarpour A, Morlot S, Raas-Rothschild A et al. Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin Genet 2006; 70: 330–5.
- Daniel-Spiegel E, Ghalamkarpour A, Spiegel R et al. Hydrops fetalis: an unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn 2005; 25: 1015–8.
- Lala S, Mulliken JB, Alomari AI et al. Gorham-Stout disease and generalized lymphatic anomaly – clinical, radiologic, and histologic differentiation. Skeletal Radiol 2013; 42: 917–24.
- Gorham LW, Stout AP. Massive osteolysis (acute spontaneous absorption of bone, phantom bone, disappearing bone); its relation to hemangiomatosis. J Bone Joint Surg Am 1955; 37–A: 985–1004.
- Moller G, Priemel M, Amling M et al. The Gorham–Stout syndrome (Gorham's massive osteolysis). A report of six cases with histopathological findings. J Bone Joint Surg Br 1999; 81: 501–6.
- Hayward PG, Orgill DP, Mulliken JB, Perez-Atayde AR. Congenital fibrosarcoma masquerading as lymphatic malformation: report of two cases. J Pediatr Surg 1995; 30: 84–8.
- Jappe U, Zimmermann T, Kahle B, Petzoldt D. Lymphangioma circumscriptum of the vulva following surgical and radiological therapy of cervical cancer. Sex Trans Dis 2002; 29: 533–5.
- Jones EW, Winkelmann RK, Zachary CB, Reda AM. Benign lymphangioendothelioma. J Am Acad Dermatol 1990; 23: 229–35.
- Guillou L, Fletcher CD. Benign lymphangioendothelioma (acquired progressive lymphangioma): a lesion not to be confused with well-differentiated angiosarcoma and patch stage Kaposi's sarcoma: clinicopathologic analysis of a series. Am J Surg Pathol 2000; 24: 1047–57.
- Kaddu S, Cerroni L, Pilatti A et al. Acral pseudolymphomatous angiokeratoma. A variant of the cutaneous pseudolymphomas. Am J Dermatopathol 1994; 16: 130–3.
- Calonje E, Fletcher CD. Sinusoidal hemangioma. A distinctive benign vascular neoplasm within the group of cavernous hemangiomas. Am J Surg Pathol 1991; 15: 1130–5.
- Herron GS, Rouse RV, Kosek JC et al. Benign lymphangioendothelioma. J Am Acad Dermatol 1994; 31: 362–8.
- Mentzel T, Kutzner H. [Tumors of the lymphatic vessel of the skin and soft tissue]. Der Pathologe 2002; 23: 118–27.
- Gimeno Aranguez M, Colomar Palmer P, Gonzalez Mediero I, Ollero Caprani JM. [The clinical and morphological aspects of childhood lymphangiomas: a review of 145 cases]. Anales espanoles de pediatria 1996; 45: 25–8.
- Ogita S, Tsuto T, Deguchi E, Tokiwa K et al. OK-432 therapy for unresectable lymphangiomas in children. J Pediatr Surg 1991; 26: 263–8; discussion 8–70.
- Dubois J, Garel L, Abela A et al. Lymphangiomas in children: percutaneous sclerotherapy with an alcoholic solution of zein. Radiology 1997; 204: 651–4.
- Luzzatto C, Midrio P, Tchaprassian Z, Guglielmi M. Sclerosing treatment of lymphangiomas with OK-432. Arch Dis Childhood 2000; 82: 316–8.
- Sainsbury DC, Kessell G, Fall AJ et al. Intralesional bleomycin injection treatment for vascular birthmarks: a 5-year experience at a single United Kingdom unit. Plast Reconstr Surg 2011; 127: 2031–44.
- Chaudry G, Guevara CJ, Rialon KL et al. Safety and efficacy of bleomycin sclerotherapy for microcystic lymphatic malformation. Cardiovasc Intervent Radiol 2014; 37: 1476–81.
- Leboulanger N, Roger G, Caze A et al. Utility of radiofrequency ablation for haemorrhagic lingual lymphangioma. Int J Pediatr Otorhinolaryngol 2008; 72: 953–8.
- Bruder E, Perez-Atayde AR, Jundt G et al. Vascular lesions of bone in children, adolescents, and young adults. A clinicopathologic reappraisal and application of the ISSVA classification. Virchows Arch 2009; 454: 161–79.
- MacLean JE, Cohen E, Weinstein M. Primary intestinal and thoracic lymphangiectasia: a response to antiplasmin therapy. Pediatrics 2002; 109: 1177–80.
- Hammill AM, Wentzel M, Gupta A et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57: 1018–24.
- Adams DM, Trenor CC, 3rd, Hammill AM et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics 2016; 137: 1–10.
- Mizuno T, Fukuda T, Emoto C et al. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infants with complicated vascular anomalies. Pediatr Blood Cancer 2017; 64:epub 2017 Feb 16.
- Hammer J, Seront E, Duez S et al. Sirolimus treatment for extensive slow-flow vascular malformations: a monocentric prospective phase-II study. Orphanet J Rare Dis 2018; 13: 191.
- Sturge WA. A case of partial epilepsy apparently due to a lesion of one of the motor centers of the brain. Trans Clin Soc London 1879; 12: 112.
- Parkes W. Right-sided hemihypertrophy resulting from right-sided congenital spastic hemiplegia with a morbid condition of the left side of the brain revealed by radiogram. J Neurol Neurosurg Psychiatry 1922; 37: 301–11.
- Thomas-Sohl KA, Vaslow DF, Maria BL. Sturge-Weber syndrome: a review. Pediatr Neurol 2004; 30: 303–10.
- Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976; 58: 218–22.
- Shirley MD, Tang H, Gallione CJ et al. Sturge–Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. New Engl J Med 2013; 368: 1971–9.
- Lee MS, Liang MG, Mulliken JB. Diffuse capillary malformation with overgrowth: a clinical subtype of vascular anomalies with hypertrophy. J Am Acad Dermatol 2013; 69: 589–94.
- Adams BB, Lucky AW. Acquired port-wine stains and antecedent trauma: case report and review of the literature. Arch Dermatol 2000; 136: 897–9.
- Larralde M, Abad ME, Luna PC, Hoffner MV. Capillary malformation-arteriovenous malformation: a clinical review of 45 patients. Int J Dermatol 2014; 53: 458–61.
- Enjolras O, Boukobza M, Jdid R. Cervical occult spinal dysraphism: MRI findings and the value of a vascular birthmark. Pediatr Dermatol 1995; 12: 256–9.
- Tavafoghi V, Ghandchi A, Hambrick GW, Jr., Udverhelyi GB. Cutaneous signs of spinal dysraphism. Report of a patient with a tail-like lipoma and review of 200 cases in the literature. Arch Dermatol 1978; 114: 573–7.
- Drolet B, Prendiville J, Golden J et al. 'Membranous aplasia cutis' with hair collars. Congenital absence of skin or neuroectodermal defect? Arch Dermatol 1995; 131: 1427–31.
- Leung AK, Telmesani AM. Salmon patches in Caucasian children. Pediatr Dermatol 1989; 6: 185–7.
- Jones EW, Orkin M. Tufted angioma (angioblastoma). A benign progressive angioma, not to be confused with Kaposi's sarcoma or low-grade angiosarcoma. J Am Acad Dermatol 1989; 20: 214–25.
- Tsang WY, Chan JK, Fletcher CD. Recently characterized vascular tumours of skin and soft tissues. Histopathology 1991; 19: 489–501.
- Catteau B, Enjolras O, Delaporte E et al. [Sclerosing tufted angioma. Apropos of 4 cases involving lower limbs]. Ann Dermatol Venereol 1998; 125: 682–7.
- Klapman MH, Yao JF. Thickening and nodules in port-wine stains. J Am Acad Dermatol 2001; 44: 300–2.
- del Pozo J, Fonseca E. Port-wine stain nodules in the adult: report of 20 cases treated by CO2 laser vaporization. Dermatol Surg 2001; 27: 699–702.
- Valeyrie L, Lebrun-Vignes B, Descamps V et al. Pyogenic granuloma within port-wine stains: an alarming clinical presentation. Eur J Dermatol 2002; 12: 373–5.
- Hofer T. Meyerson phenomenon within a nevus flammeus. The different eczematous reactions within port-wine stains. Dermatology 2002; 205: 180–3.
- Ashinoff R, Geronemus RG. Flashlamp-pumped pulsed dye laser for port-wine stains in infancy: earlier versus later treatment. J Am Acad Dermatol 1991; 24: 467–72.
- Dover JS, Geronemus R, Stern RS et al. Dye laser treatment of port-wine stains: comparison of the continuous-wave dye laser with a robotized scanning device and the pulsed dye laser. J Am Acad Dermatol 1995; 32: 237–40.
- van der Horst CM, Koster PH, de Borgie CA et al. Effect of the timing of treatment of port-wine stains with the flash-lamp-pumped pulsed-dye laser. N Engl J Med 1998; 338: 1028–33.
- Troilius A, Wrangsjo B, Ljunggren B. Potential psychological benefits from early treatment of port-wine stains in children. Br J Dermatol 1998; 139: 59–65.
- Namba Y, Mae O, Ao M. The treatment of port wine stains with a dye laser: a study of 644 patients. Scand J Plast Reconstr Surg Hand Surg 2001; 35: 197–202.
- Michel S, Landthaler M, Hohenleutner U. Recurrence of port-wine stains after treatment with the flashlamp-pumped pulsed dye laser. Br J Dermatol 2000; 143: 1230–4.
- Sapp JC, Turner JT, van de Kamp JM et al. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. Am J Med Genet A 2007; 143A: 2944–58.
- Lopez-Gutierrez JC, Lapunzina P. Capillary malformation of the lower lip, lymphatic malformation of the face and neck, asymmetry and partial/generalized overgrowth (CLAPO): report of six cases of a new syndrome/association. Am J Med Genet A 2008; 146A: 2583–8.
- Happle R. Mosaicism in human skin. Understanding the patterns and mechanisms. Arch Dermatol 1993; 129: 1460–70.
- Keppler-Noreuil KM, Rios JJ, Parker VE et al. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A 2015; 167A: 287–95.
- Martinez-Lopez A, Blasco-Morente G, Perez-Lopez I et al. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS). Clin Genet 2017; 91: 14–21.
- Ruiz-Maldonado R, Tamayo L, Laterza AM et al. Phacomatosis pigmentovascularis: a new syndrome? Report of four cases. Pediatr Dermatol 1987; 4: 189–96.
- Hagiwara K, Uezato H, Nonaka S. Phacomatosis pigmentovascularis type IIb associated with Sturge–Weber syndrome and pyogenic granuloma. J Dermatol 1998; 25: 721–9.
- Fernandez-Guarino M, Boixeda P, de Las Heras E et al. Phakomatosis pigmentovascularis: clinical findings in 15 patients and review of the literature. J Am Acad Dermatol 2008; 58: 88–93.
- Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol 2005; 141: 385–8.
- Enjolras O, Riche MC, Merland JJ. Facial port-wine stains and Sturge–Weber syndrome. Pediatrics 1985; 76: 48–51.
- Greene AK, Taber SF, Ball KL et al. Sturge–Weber syndrome: soft-tissue and skeletal overgrowth. J Craniofac Surg 2009; 20 Suppl 1: 617–21.
- Portilla P, Husson B, Lasjaunias P, Landrieu P. Sturge–Weber disease with repercussion on the prenatal development of the cerebral hemisphere. Am J Neuroradiol 2002; 23: 490–2.
- Jacoby CG, Yuh WT, Afifi AK et al. Accelerated myelination in early Sturge–Weber syndrome demonstrated by MR imaging. J Comput Assist Tomogr 1987; 11: 226–31.
- Capraro PA, Fisher J, Hammond DC, Grossman JA. Klippel–Trenaunay syndrome. Plast Reconstr Surg 2002; 109: 2052–60; quiz 61–2.
- Gucev ZS, Tasic V, Jancevska A et al. Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE) syndrome: CNS malformations and seizures may be a component of this disorder. Am J Med Genet A 2008; 146A: 2688–90.
- Cohen MM, Jr. Proteus syndrome: an update. Am J Med Genet C Semin Med Genet 2005; 137C: 38–52.
- Turner JT, Cohen MM, Jr., Biesecker LG. Reassessment of the Proteus syndrome literature: application of diagnostic criteria to published cases. Am J Med Genet A 2004; 130A: 111–22.
- Adamsbaum C, Pinton F, Rolland Y et al. Accelerated myelination in early Sturge–Weber syndrome: MRI-SPECT correlations. Pediatr Radiol 1996; 26: 759–62.
- Boukobza M, Enjolras O, Cambra M, Merland J. [Sturge–Weber syndrome. The current neuroradiologic data]. J Radiol 2000; 81: 765–71.
- Pinton F, Chiron C, Enjolras O et al. Early single photon emission computed tomography in Sturge–Weber syndrome. J Neurol Neurosurg Psychiatry 1997; 63: 616–21.
- Chugani HT, Mazziotta JC, Phelps ME. Sturge–Weber syndrome: a study of cerebral glucose utilization with positron emission tomography. J Pediatr 1989; 114: 244–53.
- Evans AL, Widjaja E, Connolly DJ, Griffiths PD. Cerebral perfusion abnormalities in children with Sturge–Weber syndrome shown by dynamic contrast bolus magnetic resonance perfusion imaging. Pediatrics 2006; 117: 2119–25.
- Huiras EE, Barnes CJ, Eichenfield LF et al. Pulmonary thromboembolism associated with Klippel–Trenaunay syndrome. Pediatrics 2005; 116: e596–600.
- Ville D, Enjolras O, Chiron C, Dulac O. Prophylactic antiepileptic treatment in Sturge–Weber disease. Seizure 2002; 11: 145–50.
- Tuxhorn IE, Pannek HW. Epilepsy surgery in bilateral Sturge–Weber syndrome. Pediatr Neurol 2002; 26: 394–7.
- Venot Q, Blanc T, Rabia SH. Targeted therapy in patients with PIK3CA-related overgrowth syndrome. Nature 2018; 558: 540–6
- Baraldini V, Coletti M, Cipolat L et al. Early surgical management of Klippel–Trenaunay syndrome in childhood can prevent long-term haemodynamic effects of distal venous hypertension. J Pediatr Surg 2002; 37: 232–5.
- Noel AA, Gloviczki P, Cherry KJ, Jr et al. Surgical treatment of venous malformations in Klippel–Trenaunay syndrome. J Vasc Surg 2000; 32: 840–7.
- Frasier K, Giangola G, Rosen R, Ginat DT. Endovascular radiofrequency ablation: a novel treatment of venous insufficiency in Klippel–Trenaunay patients. J Vasc Surg 2008; 47: 1339–45.
- Gold MH, Eramo L, Prendiville JS. Hereditary benign telangiectasia. Pediatr Dermatol 1989; 6: 194–7.
- Uhlin SR, McCarty KS, Jr. Unilateral nevoid telangiectatic syndrome. The role of estrogen and progesterone receptors. Arch Dermatol 1983; 119: 226–8.
- Pehr K, Moroz B. Cutis marmorata telangiectatica congenita: long-term follow-up, review of the literature, and report of a case in conjunction with congenital hypothyroidism. Pediatr Dermatol 1993; 10: 6–11.
- Devillers AC, de Waard-van der Spek FB, Oranje AP. Cutis marmorata telangiectatica congenita: clinical features in 35 cases. Arch Dermatol 1999; 135: 34–8.
- Gerritsen MJ, Steijlen PM, Brunner HG, Rieu P. Cutis marmorata telangiectatica congenita: report of 18 cases. Br J Dermatol 2000; 142: 366–9.
- Amitai DB, Fichman S, Merlob P et al. Cutis marmorata telangiectatica congenita: clinical findings in 85 patients. Pediatr Dermatol 2000; 17: 100–4.
- Enjolras O. [Cutis marmorata telangiectatica congenita]. Ann Dermatol Venereol 2001; 128: 161–6.
- Riviere JB, Mirzaa GM, O'Roak BJ et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 2012; 44: 934–40.
- Savitsky K, Bar-Shira A, Gilad S et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 1995; 268(5218): 1749–53.
- Hannan MA, Hellani A, Al-Khodairy FM et al. Deficiency in the repair of UV-induced DNA damage in human skin fibroblasts compromised for the ATM gene. Carcinogenesis 2002; 23: 1617–24.
- Picascia DD, Esterly NB. Cutis marmorata telangiectatica congenita: report of 22 cases. J Am Acad Dermatol 1989; 20: 1098–104.
- Gelmetti C, Schianchi R, Ermacora E. [Cutis marmorata telangiectatica congenita. 4 new cases and review of the literature]. Ann Dermatol Venereol 1987; 114: 1517–28.
- Bork K, Pfeifle J. Multifocal aplasia cutis congenita, distal limb hemimelia, and cutis marmorata telangiectatica in a patient with Adams–Oliver syndrome. Br J Dermatol 1992; 127: 160–3.
- Paller AS, Massey RB, Curtis MA et al. Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. J Pediatr 1991; 119: 917–22.
- Wollina U, Barta U, Uhlemann C, Oelzner P. Acquired nevoid telangiectasia. Dermatology 2001; 203: 24–6.
- Clayton-Smith J, Kerr B, Brunner H et al. Macrocephaly with cutis marmorata, haemangioma and syndactyly – a distinctive overgrowth syndrome. Clin Dysmorphol 1997; 6: 291–302.
- Yano S, Watanabe Y. Association of arrhythmia and sudden death in macrocephaly–cutis marmorata telangiectatica congenita syndrome. Am J Med Genet 2001; 102: 149–52.
- Mazereeuw-Hautier J, Carel-Caneppele S, Bonafe JL. Cutis marmorata telangiectatica congenita: report of two persistent cases. Pediatr Dermatol 2002; 19: 506–9.
- Iannuzzi CM, Atencio DP, Green S, et al. ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Rad Oncol Biol Phys 2002; 52: 606–13.
